RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells (Q37164573)

From Wikidata

Jump to navigation Jump to search

scientific article published on 05 March 2009

Language	Label	Description	Also known as
English	RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells	scientific article published on 05 March 2009

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells (English)

1 reference

Europe PubMed Central

18 August 2017

1 reference

based on heuristic

inferred from title

ovarian carcinoma

1 reference

based on heuristic

inferred from title

RNA interference

1 reference

based on heuristic

inferred from title

neoplastic invasiveness

1 reference

based on heuristic

inferred from title

author name string

Gyorgy Paragh

1

1 reference

Europe PubMed Central

18 August 2017

Suresh M Kumar

2

1 reference

Europe PubMed Central

18 August 2017

Zsuzsa Rakosy

3

1 reference

Europe PubMed Central

18 August 2017

Soek-Choel Choi

4

1 reference

Europe PubMed Central

18 August 2017

Xiaowei Xu

5

1 reference

Europe PubMed Central

18 August 2017

Geza Acs

6

1 reference

Europe PubMed Central

18 August 2017

language of work or name

0 references

publication date

5 March 2009

1 reference

Europe PubMed Central

18 August 2017

The American Journal of Pathology

1 reference

Europe PubMed Central

18 August 2017

174

1 reference

Europe PubMed Central

18 August 2017

4

1 reference

Europe PubMed Central

18 August 2017

1504-1514

1 reference

Europe PubMed Central

18 August 2017

Effects of recombinant erythropoietin on breast cancer-initiating cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

6 September 2017

Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

6 September 2017

Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

6 September 2017

Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

6 September 2017

Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

6 September 2017

Cancer-related anemia and recombinant human erythropoietin--an updated overview

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

6 September 2017

Erythropoietin biology in cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

6 September 2017

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

6 September 2017

Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

6 September 2017

Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

6 September 2017

rHuEPO and treatment outcomes: the clinical experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

6 September 2017

Molecular biology of erythropoietin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

6 September 2017

Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

6 September 2017

Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

6 September 2017

Functional significance of erythropoietin receptor expression in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

6 September 2017

Regulation of the erythropoietin gene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

6 September 2017

JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

6 September 2017

The regulated expression of erythropoietin by two human hepatoma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

6 September 2017

Human recombinant erythropoietin does not promote cancer growth in presence of functional receptors expressed in cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

14 September 2017

Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

14 September 2017

Survival and invasiveness of astrocytomas promoted by erythropoietin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

14 September 2017

Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

14 September 2017

Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

14 September 2017

Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

14 September 2017

Erythropoietin receptor function and expression in epithelial ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

14 September 2017

Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

14 September 2017

The erythropoietin-receptor pathway modulates survival of cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

14 September 2017

Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

14 September 2017

Activation of the transcription factor NF-kappaB by the erythropoietin receptor: structural requirements and biological significance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

28 September 2017

Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

28 September 2017

Wortmannin, a specific inhibitor of phosphatidylinositol-3-kinase, inhibits erythropoietin-induced erythroid differentiation of K562 cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

28 September 2017

Activation of the mitogen-activated protein kinase pathway by the erythropoietin receptor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

28 September 2017

Autocrine stimulation by erythropoietin (Epo) requires Epo secretion.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

28 September 2017

Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

27 June 2018

Erythropoietin and erythropoietin receptor expression in human cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

27 June 2018

Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

3 September 2018

Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

3 September 2018

Prognostic significance of erythropoietin expression in human endometrial carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671380

3 September 2018

Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19264915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erythropoietin stimulates proliferation of human renal carcinoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19264915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/19264915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Breast cancer trial with erythropoietin terminated unexpectedly

1 reference

https://pubmed.ncbi.nlm.nih.gov/19264915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19264915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models

1 reference

https://pubmed.ncbi.nlm.nih.gov/19264915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Do erythropoietin receptors on cancer cells explain unexpected clinical findings?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19264915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correction of anemia with epoetin alfa in chronic kidney disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19264915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2353/AJPATH.2009.080592

1 reference

Europe PubMed Central

18 August 2017

release_hq6jtz3iafct3hl4grpih3hhhu

1 reference

https://api.fatcat.wiki/v0/release/hq6jtz3iafct3hl4grpih3hhhu

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37164573&oldid=1843717300"